N/A N=73 Effect of Sedation on Diagnostic Injections
Sacroiliac Joint Pain · Sympathetically Maintained Pain
Primary: Pain Score — 2.2; 3.4 units on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=57 Omega-3 Fatty Acids for Hyperactivity Treatment in Autism Spectrum Disorder
Autism Spectrum Disorders · Hyperactivity
Primary: Change in Aberrant Behavior Checklist - Hyperactivity Subscale (ABC-H) Score — -5.3; -3.4 units on a scale
Phase 3 N=723 Efficacy and Safety Study of Nicotine Mint Lozenge (2mg and 4mg) in Smoking Cessation
Smoking
Primary: Rate of Successful Smoking Cessation at Week 6 — 24.48; 21.49; 30.83; 20.17 Percentage of participants — p=0.3851
Phase 3 N=934 Safety and Efficacy of BI 1744 CL in Patients With Chronic Obstructive Pulmonary Disease II
Pulmonary Disease, Chronic Obstructive
Primary: Forced Expiratory Volume in One Second (FEV1) Area Under Curve 0-3 Hour (h) (AUC 0-3h) Response at 24 Weeks — -0.013; 0.116; 0.140; 0.137 Liter — p=<0.0001
Phase 2 N=33 Everolimus (RAD001) in Primary Therapy of Waldenstrom's Macroglobulinemia
Waldenstrom's Macroglobulinemia
Primary: Overall Response Rate of RAD001 in Patients With Previously Untreated WM — 22 participants
Phase 3 N=326 Safety Trial of Naproxen Sodium/ Diphenhydramine
Pain
Primary: Percentage of Subjects With Any Adverse Event for Those Subjects Who Were Randomized and Took at Least One Dose of Investigational Product — 39.6; 45.0 Percentage of…
Phase 2 N=24 Dalfampridine for Imbalance in Multiple Sclerosis
Multiple Sclerosis · Fatigue
Primary: Change in Automatic Postural Response (APR )Latency — 5.71; 4.58 milliseconds — p=0.51
Phase 2 N=100 4 Weeks Treatment With Empagliflozin (BI 10773) in Japanese Type 2 Diabetic Patients (T2DM)
Diabetes Mellitus, Type 2
Primary: Change From Baseline in Urine Glucose Excretion — 599.763; 43428.245; 81564.440; 89189.527 mg — p=<0.0001
N/A N=166 Safety of Continuing Metformin in Diabetic Patients With Normal Kidney Function Receiving Contrast Media
Diabetes Mellitus · Lactic Acidosis
Primary: Incidence of Lactic Acidosis — 0; 0 participants
N/A N=36 Nutritional Status and Enteral Absorption Capability After Brain Death
Brain Death
Primary: Primary Outcome Measure is IL-6 Level — 565.5; 264.9 pg/ml
Phase 2 N=386 A Study of TMC435 in Combination With Pegylated Interferon Alp\Fa-2a and Ribavirin in Patients Infected With Genotype 1 Hepatitis C Virus Who Never Received Treatment
Hepatitis C
Primary: The Percentage of Participants Achieving a Sustained Virologic Response at Week 72 (SVRW72) — 80.8; 70.7; 77.9; 84.8 Percentage of participants — p=0.051
N/A N=19 High MAP in Septic Shock With Hypertension
Septic Shock
Primary: Mean Arterial Pressure — 90 mmHg
Phase 2 N=24 Assessing the PK and Effect on Glucose and GI Hormone Concentrations of Metformin Delayed-Release in Subjects With T2DM
Type 2 Diabetes Mellitus
Primary: Area Under the Curve (0-t) of Plasma Metformin — 8672; 4774; 3842; 8075 ng*h/mL
Phase 2 N=659 Empagliflozin (BI 10773) in Type Two Diabetes (T2D) Patients, Open Label Extension
Diabetes Mellitus, Type 2
Primary: Hypoglycaemic Events — 0.9; 1.8; 7.1; 2.4 percentage of participants
Phase 2 N=495 BI 10773 add-on to Metformin in Patients With Type 2 Diabetes
Diabetes Mellitus, Type 2
Primary: Change From Baseline in HbA1c After 12 Weeks of Treatment — 0.15; -0.09; -0.23; -0.56 percentage of HbA1c — p=0.0226